AML1/ETO and its function as a regulator of gene transcription via epigenetic mechanisms
K Rejeski, J Duque-Afonso, M Lübbert - Oncogene, 2021 - nature.com
Abstract The chromosomal translocation t (8; 21) and the resulting oncofusion gene
AML1/ETO have long served as a prototypical genetic lesion to model and understand …
AML1/ETO have long served as a prototypical genetic lesion to model and understand …
Origins of aberrant DNA methylation in acute myeloid leukemia
T Schoofs, WE Berdel, C Müller-Tidow - Leukemia, 2014 - nature.com
Aberrant DNA methylation patterns are a characteristic feature of cancer including myeloid
malignancies such as acute myeloid leukemia (AML). The mechanisms behind aberrant …
malignancies such as acute myeloid leukemia (AML). The mechanisms behind aberrant …
Depletion of RUNX1/ETO in t (8; 21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding
A Ptasinska, SA Assi, D Mannari, SR James… - Leukemia, 2012 - nature.com
Abstract The t (8; 21) translocation fuses the DNA-binding domain of the hematopoietic
master regulator RUNX1 to the ETO protein. The resultant RUNX1/ETO fusion protein is a …
master regulator RUNX1 to the ETO protein. The resultant RUNX1/ETO fusion protein is a …
Interaction of c-Myb with p300 is required for the induction of acute myeloid leukemia (AML) by human AML oncogenes
DR Pattabiraman, C McGirr… - Blood, The Journal …, 2014 - ashpublications.org
The MYB oncogene is widely expressed in acute leukemias and is important for the
continued proliferation of leukemia cells, suggesting that MYB may be a therapeutic target in …
continued proliferation of leukemia cells, suggesting that MYB may be a therapeutic target in …
RUNX1/RUNX1T1 mediates alternative splicing and reorganises the transcriptional landscape in leukemia
The fusion oncogene RUNX1/RUNX1T1 encodes an aberrant transcription factor, which
plays a key role in the initiation and maintenance of acute myeloid leukemia. Here we show …
plays a key role in the initiation and maintenance of acute myeloid leukemia. Here we show …
AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches
MA Hatlen, L Wang, SD Nimer - Frontiers of medicine, 2012 - Springer
The AML1-ETO fusion transcription factor is generated by the t (8; 21) translocation, which is
present in approximately 4%–12% of adult and 12%–30% of pediatric acute myeloid …
present in approximately 4%–12% of adult and 12%–30% of pediatric acute myeloid …
AML1/ETO cooperates with HIF1α to promote leukemogenesis through DNMT3a transactivation
The mechanisms by which AML1/ETO (A/E) fusion protein induces leukemogenesis in acute
myeloid leukemia (AML) without mutagenic events remain elusive. Here we show that …
myeloid leukemia (AML) without mutagenic events remain elusive. Here we show that …
ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia
Additional sex combs-like (ASXL) proteins are mammalian homologues of additional sex
combs (Asx), a regulator of trithorax and polycomb function in Drosophila. While there has …
combs (Asx), a regulator of trithorax and polycomb function in Drosophila. While there has …
Epigenetic alterations in acute myeloid leukemias
Acute myeloid leukemia (AML) is a heterogeneous disease for which the standard treatment
with cytotoxic chemotherapy has remained largely unchanged for over four decades, with …
with cytotoxic chemotherapy has remained largely unchanged for over four decades, with …